Although RB1 alterations were relatively rare at baseline among patients treated with ribociclib (1.6%), their prevalence increased to 10% at the end-of-treatment (EOT) when comparing genomic alterations in paired baseline and EOT circulating tumor DNA samples from the ribociclib arm 72. This evidence concerns the gene RB1 and neoplasm.